Inhibikase Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Inhibikase Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2020 to 2023.
  • Inhibikase Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $148K, a 14.1% increase year-over-year.
  • Inhibikase Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $354K, a 25.9% decline year-over-year.
  • Inhibikase Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $500K, a 9.17% increase from 2022.
  • Inhibikase Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $458K, a 70.1% decline from 2021.
  • Inhibikase Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $1.53M, a 167% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $500K +$42K +9.17% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-27
2022 $458K -$1.07M -70.1% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-27
2021 $1.53M +$958K +167% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-31
2020 $574K Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.